Factors influencing survival of 107 HER2 positive breast cancer patients treated with trastuzumab based neoadjuvant chemotherapy

被引：1
|
作者：
Favier, L. [1 ]
Guiu, S. [1 ]
Dunach, E. [1 ]
Assous, D. [1 ]
Bonnetain, F. [1 ]
Gligorov, J. [2 ]
Stockmeier, V. [3 ]
Vasseur, B. [4 ]
Fumoleau, P. [1 ]
Coudert, B. [1 ]
机构：
[1] Ctr Georges Francois Leclerc, Dijon, France
[2] Hop Tenon, F-75970 Paris, France
[3] Lab Sanofi Aventis, Paris, France
[4] Lab Roche, Paris, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70820-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5058
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [1] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    P. S. Blanchette
    D. N. Desautels
    G. R. Pond
    J. M. S. Bartlett
    S. Nofech-Mozes
    M. J. Yaffe
    K. I. Pritchard
    Breast Cancer Research and Treatment, 2018, 170 : 169 - 177
  • [2] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M.
    Pritchard, K. I.
    CANCER RESEARCH, 2017, 77
  • [3] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G. R.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M. J.
    Pritchard, K. I.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) : 169 - 177
  • [4] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
  • [5] Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab
    Fujita, Noriko
    Enomoto, Yukie
    Inakami, Keiko
    Yanagisawa, Tetsu
    Iguchi, Chikage
    Aono, Toyokazu
    Nomura, Takashi
    Yamamoto, Hitoshi
    Kasugai, Tsutomu
    Shiba, Eiichi
    ONCOLOGY, 2020, 98 (01) : 35 - 41
  • [6] Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico
    Villarreal-Garza, Cynthia
    Soto-Perez-de-Celis, Enrique
    Sifuentes, Erika
    Ruano, Santiago
    Baez-Revueltas, Berenice
    Lara-Medina, Fernando
    Arce-Salinas, Claudia
    Alvarado-Miranda, Alberto
    Chavarri-Guerra, Yanin
    Caro-Sanchez, Claudia
    Castaneda-Soto, Noel
    Bargallo-Rocha, Enrique
    Mohar, Alejandro
    BREAST, 2015, 24 (03): : 218 - 223
  • [7] Risk factors and clinical relevance of cardiotoxicity in her2 positive breast cancer patients treated with trastuzumab
    Minguito Carazo, C. Carlos
    Lopez Flores, M.
    Sanchez Cousido, L. F.
    Lopez Gonzalez, A.
    Rodriguez Santamarta, M.
    Tundidor Sanz, E.
    Echarte Morales, J.
    Sanchez Munoz, E.
    Garcia Palomo, A.
    Fernandez Vazquez, F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 37 - 37
  • [8] DOES PREVIOUS NEOADJUVANT/ADJUVANT TRASTUZUMAB INFLUENCE THE DISEASE OUTCOME OF METASTATIC HER2 POSITIVE BREAST CANCER PATIENTS TREATED WITH FIRST LINE TRASTUZUMAB AND CHEMOTHERAPY
    Milosevic, Snezana
    Stanic, Nemanja
    Bozovic-Spasojevic, Ivana
    Tomasevic, Zorica
    Susnjar, Snezana
    BREAST, 2015, 24 : S41 - S42
  • [9] Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.
    Tiwari, Shruti Rakesh
    Raska, Paola
    Moore, Halle C. F.
    Emamekhoo, Hamid
    Abraham, Jame
    Budd, G. Thomas
    Montero, Alberto J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
    Antolin, Silvia
    Garcia-Caballero, Lucia
    Reboredo, Cristina
    Molina Diaz, Aurea
    Mosquera, Joaquin
    Vazquez-Boquete, Angel
    Gallego, Rosalia
    Paz Santiago, Maria
    Concha, Angel
    Eva Perez, Maria
    Calvo, Lourdes
    Garcia-Caballero, Tomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345